[
    {
        "file_name": "nlspharmaceuticsltd_20200228_f-1_ex-10.14_12029046_ex-10.14_development agreement.pdf",
        "perturbation": [
            {
                "type": "Inconsistencies - Legal Contradiction",
                "original_text": "Upon signature of this Agreement and no later than 20 days following it, Eurofarma shall pay to NLS, for the rights pursuant to Article 2.1(i), the non-refundable and non-deductible sum of USD 2’500’000 (in words: US dollars two and a half million).",
                "changed_text": "Upon signature of this Agreement and no later than 60 days following it, Eurofarma shall pay to NLS, for the rights pursuant to Article 2.1(i), the non-refundable and non-deductible sum of USD 2’500’000 (in words: US dollars two and a half million).",
                "explanation": "Payment terms modified to be 60 days which may conflict with prompt payment laws in some jurisdictions. Brazil has laws for prompt payments to businesses and contractors.",
                "contradicted_law": "Brazilian Federal Law No. 8.666/93 which states that public entities must make payments within 30 days, otherwise interests apply.",
                "location": "3.1"
            },
            {
                "type": "Inconsistencies - Legal Contradiction",
                "original_text": "Royalty payments shall be paid quarterly within thirty (45) days following the close of the calendar quarter.",
                "changed_text": "Royalty payments shall be paid quarterly within ninety (90) days following the close of the calendar quarter.",
                "explanation": "Increased payment timeframe to 90 days, potentially violating prompt payment regulations that mandate shorter payment cycles. In Brazil, if the payment is not made, there would be late payment interests.",
                "contradicted_law": "Article 39-A of Law 4.886/65 amended by Law 6.244/75 in Brazil states payments must be made by the 20th day of the subsequent month of issuance of the invoice.",
                "location": "3.3"
            },
            {
                "type": "Inconsistencies - Legal Contradiction",
                "original_text": "Such records shall be retained by the Licensee for ten (10) years following a given reporting period.",
                "changed_text": "Such records shall be retained by the Licensee for two (2) years following a given reporting period.",
                "explanation": "Reduced the record retention period to 2 years, which may conflict with regulatory requirements for pharmaceutical records retention in Brazil. Pharmaceutical records must be kept for a certain period to enable an audit trail.",
                "contradicted_law": "Resolution RDC 91/2001 requires that pharmaceutical companies keep records for 5 years.",
                "location": "3.5"
            }
        ]
    }
]